Canadian biopharmaceutical firm Arbutus Biopharma has identified many molecules that can inhibit the SARS-CoV-2 nsp5 main protease (Mpro), achieving its first milestone under Covid-19 discovery research and license deal.
Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform.
Baidu, an AI company with internet foundation, has agreed to integrate its messenger ribonucleic acid (mRNA) design optimisation platform LinearDesign, into biopharmaceutical company Sanofi's product design pipeline.
Danish pharma company Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals and its ribonucleic acid interference (RNAi) platform in a deal valued at $3.3bn, to expand the RNAi technology use.
Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash.
Acelyrin has raised $250m through the series B financing round to license and acquire other programmes with focus on immunology.
AbbVie has extended a collaboration agreement with the University of Chicago until 2025 to support preclinical research in oncology.
Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.
Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma.
Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.